Finally, the recent approval of thrombopoietin receptor agonists for use in CLD patients paves a way for a safe and effective alternative method of improving platelet levels and reducing the need for recurrent platelet transfusions. The gene discussed is MPL; the disease is congenital secretory chloride diarrhea 1.